Leo Pharma

This study tested whether a higher dose of the drug brodalumab works better for people with moderate-to-severe plaque psoriasis who weigh at least 120 kg. 385 participants received either an adjustable higher dose or the standard dose for 52 weeks. The main goal was to see if mor…

This study tested an ointment called TMB-001 for people aged 6 and older with a genetic skin condition that causes severe scaling and cracking (ichthyosis). 153 participants applied the ointment daily for 12 weeks. The goal was to see if it could improve skin scaling and fissures…

This study tested the drug tralokinumab in 28 children aged 6 to 12 with moderate-to-severe atopic dermatitis (eczema) that did not improve with standard creams. The goal was to see how the drug moves through the body and whether it is safe. Children received injections for up to…

This study tested a cream called delgocitinib, applied twice daily, in 362 Chinese adults and adolescents (ages 12-17) with moderate to severe chronic hand eczema. The main goal was to see if the cream could clear or nearly clear the eczema after 16 weeks compared to a cream with…

This study tested a drug called tralokinumab for people with moderate-to-severe atopic hand eczema that hasn't improved with standard treatments. 235 adults received either the drug or a placebo every two weeks for 16 weeks, then everyone got the drug for another 16 weeks. The go…

This study tested a cream called delgocitinib on teens aged 12-17 with moderate to severe chronic hand eczema. Participants applied the cream or a placebo twice daily for 16 weeks. The goal was to see if the cream clears or nearly clears the eczema and improves quality of life.

This study tested a new ointment (LEO 90100) against a standard one (Daivobet) for stable plaque psoriasis in 604 Chinese adults. Participants applied the treatment for 4 weeks. The goal was to see if the new ointment could clear or nearly clear psoriasis patches better than the …

This study tested two strengths of an ointment (TMB-001) in 34 people aged 9 and older with congenital ichthyosis, a rare genetic condition causing thick, scaly skin. The goal was to see if the ointment could safely reduce scaling and improve skin appearance. Participants applied…

This study tested a new medicine called LEO 138559 (Temtokibart) in 262 adults with moderate-to-severe atopic dermatitis (eczema). Participants received one of four doses or a placebo as injections under the skin for 16 weeks. The goal was to see how well the drug reduces eczema …

This early-phase trial tested a single injection of LEO 158968 in 6 people experiencing a gout flare. The main goal was to see if the drug could reduce joint pain to none or mild within a few days. Researchers also monitored safety and how the body processed the drug. Because it …

This phase 2a trial tested whether a new ointment called LEO 124249 can improve chronic hand eczema when applied twice daily for up to 8 weeks. 91 adults with hand eczema that didn't respond well to steroid creams took part. The study compared the active ointment to an inactive v…

This early-stage trial tested the safety and tolerability of a new drug called LEO 153339 in 108 healthy adults. Participants received either a single dose or multiple doses of the drug or a placebo. The study focused on how the body absorbs and processes the drug, and whether it…

This early-stage trial tested whether delgocitinib cream, a potential eczema treatment, makes skin more sensitive to light. Thirty-five healthy adults received a single application of the cream and a placebo on different skin spots, then were exposed to UV light. Researchers chec…

This completed Phase 1 trial tested whether delgocitinib cream, a potential eczema treatment, can cause a UV-light-induced allergic skin reaction (photoallergy). Sixty healthy adults had the cream or a placebo applied to their skin and were then exposed to UV light. Researchers c…

This early-stage trial tested a new compound called LEO 158968 in 120 healthy adults aged 18 to 60. The main goal was to check for side effects and see how well the drug is tolerated, as well as how it moves through and leaves the body. Participants received either the drug or a …

This study looked at whether the drug delgocitinib changes heart rhythms in 40 healthy adults. Participants took the drug or a placebo, and their heart activity was measured with ECGs. The goal was to check for possible heart risks, not to treat any disease. Since it involved hea…

This early-stage study tested how much of the drug tacrolimus gets into the bloodstream when applied twice daily to healthy skin. Twenty-four healthy adults took part. The goal was to measure drug levels and check for side effects, not to treat any disease.

This study looked at how a single dose of tralokinumab moves through the body when given by two different injection devices. 101 healthy adults aged 18 to 55 took part. The goal was to compare drug levels and safety, not to treat any disease.